Sarepta Therapeutics reported $94.02M in Trade Creditors for its fiscal quarter ending in September of 2025.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 21.75M 1.65M Sep/2025
Agios Pharmaceuticals USD 19.55M 2.02M Sep/2025
Alnylam Pharmaceuticals USD 117.59M 15.2M Sep/2025
Amgen USD 19.64B 1.61B Sep/2025
Biogen USD 413.1M 4.7M Sep/2025
BioMarin Pharmaceutical USD 798.44M 114.19M Sep/2025
Daiichi Sankyo JPY 568.5B 16.84B Dec/2025
Eli Lilly USD 4.26B 186.5M Sep/2025
Gilead Sciences USD 808M 226M Sep/2025
Incyte USD 171.92M 1.24B Sep/2025
Insmed USD 79.59M 1.24M Sep/2025
Ionis Pharmaceuticals USD 14.33M 8.47M Sep/2025
Moderna USD 267M 92M Sep/2025
Neurocrine Biosciences USD 119.9M 15.3M Sep/2025
Pfizer USD 5.02B 142M Sep/2025
PTC Therapeutics USD 36.62M 169.69M Sep/2025
Regeneron Pharmaceuticals USD 5.83B 4.93B Dec/2025
Roche Holding CHF 5.78B 1.27B Dec/2025
Sanofi EUR 22.93B 927M Dec/2025
Sarepta Therapeutics USD 94.02M 42.69M Sep/2025
Tectonic Therapeutic USD 1.48M 1.32M Sep/2025
Ultragenyx Pharmaceutical USD 40.57M 6.33M Sep/2025
Vertex Pharmaceuticals USD 4.03B 320.8M Sep/2025